Rasmussen Encephalitis

Overview

• Definition: Rasmussen Encephalitis (RE), also known as chronic focal encephalitis, is a rare, severe, progressive inflammatory neurological disorder affecting primarily one cerebral hemisphere. It is characterized by intractable focal epilepsy, progressive hemiparesis, and cognitive deterioration. The condition typically manifests in childhood, though adult-onset cases have been reported.

• Epidemiology:

  • Incidence: Extremely rare, estimated at 2.4 cases per 10 million children annually in Europe.
  • Age of onset: Typically between 1 and 10 years, with a peak incidence between 3 and 7 years. Approximately 10% of cases occur in adolescents or adults (age >10 years).
  • Gender: No significant gender predominance.
  • Prevalence: Unknown due to its rarity.

• Classification:

  • While there are no formal classifications, RE can be broadly considered by age of onset:
    • Classic/Childhood-onset RE: The most common form, presenting in early childhood with typical progressive course.
    • Adult-onset RE: Accounts for a smaller proportion of cases, often with a slower progression and potentially milder initial symptoms, though the ultimate prognosis remains severe.

Pathophysiology

• Mechanism: The exact pathophysiology of RE is not fully understood, but it is considered an autoimmune disease directed against neuronal and glial elements within one cerebral hemisphere.

  • Immune-mediated destruction: Evidence suggests a prominent role for cytotoxic T-lymphocytes (CD8+) targeting neurons and glia.
  • Autoantibodies: While antibodies against the GluA2 subunit of the AMPA receptor have been identified in some patients, their presence is not consistent across all cases, and their direct pathogenic role remains debated. Other potential targets include anti-Munc18 antibodies.
  • Inflammation: Chronic inflammation leads to neuronal loss, glial proliferation (astrogliosis), and microglial activation, resulting in progressive cerebral atrophy.
  • Viral triggers: While not definitively proven, some hypotheses propose a viral trigger (e.g., enteroviruses, Epstein-Barr virus, cytomegalovirus) initiating an autoimmune response in genetically predisposed individuals. No specific virus has been consistently identified.
  • Genetic predisposition: No specific genetic markers have been identified, but the observation of familial cases in some autoimmune conditions suggests a potential, though unproven, genetic susceptibility.

• Risk Factors:

  • Age: Childhood (1-10 years) is the primary age of risk.
  • Autoimmune predisposition: While not a direct risk factor, individuals with other autoimmune disorders or a family history of autoimmunity might theoretically have an increased susceptibility, though this is not well-established for RE.

• Protective Factors: None definitively identified. Early diagnosis and immunomodulatory treatment may slow progression but do not prevent the disease.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:

  • Intractable Focal Seizures: Often the presenting symptom, characterized by focal motor seizures (e.g., epilepsia partialis continua - EPC), which are often refractory to multiple anti-seizure medications (ASMs). Hemiconvulsions are common.
  • Progressive Hemiparesis: Weakness affecting one side of the body, gradually worsening over months to years.
  • Cognitive Deterioration: Progressive decline in intellectual function, memory, language, and executive functions, commensurate with the cerebral hemisphere affected.

• Early Signs:

  • Focal motor seizures, often starting as subtle twitching of an extremity or face on one side.
  • Occasional sensory symptoms (e.g., paresthesia).
  • Subtle motor deficits that may be initially overlooked.

• Advanced Signs:

  • Established hemiparesis or hemiplegia.
  • Severe cognitive impairment, often leading to global developmental delay in children.
  • Epilepsia partialis continua (EPC) – continuous or nearly continuous focal clonic movements, primarily affecting a distal limb or facial muscles, often persisting through sleep, highly characteristic but not pathognomonic.
  • Hemianopia (visual field defect).
  • Dysphasia/aphasia if the dominant hemisphere is affected.

• Atypical Presentations:

  • Adult-onset RE: May present with a slower, more insidious course, less severe initial seizures, or a predominant cognitive decline. Hemiparesis may be less pronounced.
  • Bilateral RE: Extremely rare, reported in a few cases, posing significant diagnostic challenges.
  • Exclusively cognitive decline: In rare instances, cognitive decline may precede seizures or motor deficits.

Physical Examination

• Inspection:

  • Hemiatrophy of the affected limbs (later stage).
  • Abnormal posturing or dystonia (due to chronic spasticity).
  • Evidence of seizure activity (e.g., EPC) during the examination.
  • Subtle facial asymmetry.

• Palpation: Not typically yielding specific findings.

• Special Tests:

  • Neurological examination: Detailed assessment of motor strength (revealing hemiparesis), deep tendon reflexes (often hyperreflexia on the affected side), Babinski sign (extensor plantar response), and sensory deficits.
  • Neuropsychological assessment: Essential for quantifying cognitive deficits and tracking decline over time. This includes evaluation of language, memory, attention, executive functions, and visual-spatial skills.

Diagnostic Approach

History Taking

• Key Questions:

  • Detailed seizure history: Age of onset, seizure type (focal motor), frequency, duration, response to ASMs, presence of EPC.
  • Onset and progression of motor weakness: When started, how it progressed, current functional limitations.
  • Cognitive and developmental history: Baseline development, onset of cognitive decline, academic performance changes, specific deficits (language, memory).
  • Associated symptoms: Visual disturbances, balance issues, behavioral changes.
  • Family history of neurological or autoimmune disorders.
  • Past medical history, infectious illnesses.

• Red Flags:

  • Unilateral, intractable focal seizures, especially EPC.
  • Rapidly progressive hemiparesis and cognitive decline in a child.
  • Lack of response to multiple ASMs.
  • MRI findings suggestive of unilateral inflammation and atrophy.

Laboratory Tests

• First-Line:

  • Routine blood tests: Complete blood count, electrolytes, liver and renal function tests (to rule out metabolic causes of seizures, monitor ASM side effects).
  • Cerebrospinal Fluid (CSF) analysis:
    • Mild pleocytosis (lymphocytic) may be present in a minority of cases, usually <50 cells/mm³.
    • Normal protein and glucose levels.
    • Oligoclonal bands are rarely positive.
    • Rule out infectious causes (viral PCR, bacterial/fungal cultures).
    • Antibody testing: Anti-GluA2 antibodies can be tested in CSF, though their role as a definitive diagnostic marker is limited by their inconsistent presence. Other neuronal surface antibodies (e.g., anti-LGI1, anti-NMDA-R) should be ruled out.

• Confirmatory: No single laboratory test is confirmatory. Diagnosis is clinical-radiological-histopathological.

  • Brain Biopsy: The definitive diagnostic tool, though often reserved for atypical cases or when surgical intervention (hemispherectomy) is planned.
    • Histopathology: Shows perivascular lymphocytic cuffing (predominantly CD8+ T cells), microglial activation, astrogliosis, and extensive neuronal loss. In later stages, there is significant cortical atrophy.

• Monitoring: Not applicable for diagnosis, but relevant for seizure management and treatment side effects.

Imaging

• Recommended:

  • Brain MRI with and without contrast: The cornerstone of radiological diagnosis.
    • Early stage: May be normal or show subtle cortical edema/signal changes (hyperintensity on T2-weighted and FLAIR sequences) in the affected hemisphere.
    • Later stages: Progressive findings include:
      • Unilateral cortical atrophy (narrowing of gyri and widening of sulci).
      • Ventricular enlargement (ipsilateral).
      • Increased T2/FLAIR signal in the gray and white matter of the affected hemisphere, indicating inflammation, gliosis, and neuronal loss.
      • Patchy or subtle leptomeningeal enhancement may be seen with contrast in some inflammatory phases.
      • Loss of gray-white matter differentiation.
    • Serial MRIs: Essential to demonstrate the progressive nature of unilateral atrophy and signal changes.

• Advanced:

  • FDG-PET (Positron Emission Tomography):
    • Typically shows unilateral hypometabolism (decreased glucose uptake) in the affected cerebral hemisphere, often more extensive than atrohy seen on MRI, reflecting neuronal dysfunction. Can be useful in early stages when MRI changes are subtle. Hypermetabolism may be seen initially at seizure onset.
  • SPECT (Single-Photon Emission Computed Tomography):
    • Ictal SPECT may show unilateral hyperperfusion during seizures, while interictal SPECT may show hypoperfusion. Can help localize the seizure onset zone.
  • Functional MRI (fMRI): Can be used pre-surgically to map eloquent cortex (language, motor) and assess reorganization in the unaffected hemisphere.
  • Diffusion Tensor Imaging (DTI): May show abnormalities in white matter tracts reflecting axonal damage.

Management

Acute Management

• Immediate:

  • Seizure control: Initial focus is on aggressive seizure management, particularly for status epilepticus or EPC. This involves benzodiazepines (lorazepam, diazepam), followed by intravenous ASMs (e.g., fosphenytoin, levetiracetam, lacosamide, valproate).
  • Airway protection: As needed during severe seizures.

• Stabilization:

  • Optimization of ASMs: Titrating multiple ASMs (typically 2-3) to achieve the best possible seizure control. No single ASM is superior for RE.
  • Baseline neurological and cognitive assessment.

• Emergency:

  • Status epilepticus management: Standard protocols.
  • Immunotherapy in acute phase: In cases with very rapid progression or acute exacerbations, high-dose corticosteroids (methylprednisolone 20-30 mg/kg/day IV for 3-5 days) or intravenous immunoglobulins (IVIg, 2 g/kg over 2-5 days) may be considered, though evidence of their long-term efficacy in halting RE progression is limited. Plasmapheresis can be considered in acute, severe cases unresponsive to corticosteroids/IVIg.

Chronic Management

• Pharmacological:

  • Anti-Seizure Medications (ASMs): Continue multiple ASMs, often at high doses, to reduce seizure frequency and severity. Complete seizure freedom is rare. Common ASMs include: valproate, levetiracetam, carbamazepine, oxcarbazepine, clobazam, phenobarbital, topiramate, lacosamide, perampanel. Ketogenic diet may be considered as an adjunctive therapy.
  • Immunomodulatory Therapy: While ASMs control symptoms, immunomodulatory therapies aim to slow disease progression.
    • Corticosteroids: Chronic low-dose oral corticosteroids may be used, but long-term use is limited by side effects.
    • Intravenous Immunoglobulins (IVIg): Monthly or bimonthly infusions (0.4-1 g/kg/dose) are often used to reduce seizure frequency and potentially slow disease progression, especially in refractory cases or those not yet eligible for surgery.
    • Rituximab: A monoclonal antibody targeting CD20 B cells, used in some severe, progressive, or adult-onset cases. Limited evidence but can be considered.
    • Tacrolimus/Mycophenolate Mofetil: Immunosuppressants used in some resistant cases, usually after considering surgery or when surgery is not an option. Limited data on efficacy.

• Non-pharmacological:

  • Hemispherectomy: The most effective treatment for stopping seizures and disease progression in classic RE, leading to seizure freedom in a high percentage of patients. It involves surgical removal or functional disconnection of the affected cerebral hemisphere.
    • Candidates: Children with unilateral intractable epilepsy, progressive hemiparesis, cognitive decline, and clear evidence of unilateral disease on imaging, and with sufficient functional plasticity in the other hemisphere.
    • Types: Anatomic hemispherectomy (removal), functional hemispherectomy (disconnection), peri-insular hemispherotomy (less invasive disconnection).
  • Rehabilitation: Essential to manage deficits resulting from disease and surgery.
    • Physical therapy: To maximize motor function, prevent contractures, and aid ambulation.
    • Occupational therapy: To improve activities of daily living and adaptive skills.
    • Speech therapy: For language deficits.
    • Cognitive rehabilitation: To address cognitive impairment.
  • Nutritional support: Important for children with prolonged illness or severe disability.
  • Psychosocial support: For patients and families coping with a chronic, severe illness.

• Monitoring:

  • Seizure diary: Continuous tracking of seizure frequency and severity.
  • Regular neurological exams: To assess progression of hemiparesis and other focal deficits.
  • Serial neuropsychological testing: To monitor cognitive decline or stability post-treatment.
  • Serial brain MRIs: To monitor for progression of atrophy and signal changes, and evaluate post-surgical changes.
  • EEG monitoring: Regular EEGs to assess interictal and ictal epileptiform activity.

Treatment Algorithms

• First-Line:

  1. Diagnosis Confirmation: Clinical suspicion, MRI, EEG findings. Consider brain biopsy if atypical or for confirmation pre-surgery.
  2. Anti-Seizure Medications (ASMs): Optimize combination of 2-3 ASMs to control seizures, recognizing that total seizure freedom is unlikely without definitive surgery.
  3. Immunomodulatory Therapy: Initiate with IVIg or high-dose corticosteroids, especially if rapid progression or acute worsening. Ongoing IVIg is common.

• Second-Line:

  1. Hemispherectomy: If seizures remain intractable, and there is clear evidence of unilateral disease progression, hemispherectomy becomes the gold standard treatment for seizure control and halting disease progression. This is usually considered after 6-12 months of failed medical therapy.
  2. Alternative Immunosuppressants: If hemispherectomy is not an option or as an adjunct for persistent inflammation (e.g., Rituximab, tacrolimus, mycophenolate mofetil).

• Refractory Cases:

  • For patients where hemispherectomy is not feasible or fails, continued multidisciplinary supportive care, ongoing ASM optimization, and exploration of novel immunotherapeutic experimental approaches become the mainstays. Palliative care may be relevant for severe cognitive and motor decline.

Complications

• Common:

  • Intractable Epilepsy: Multiple daily seizures significantly impacting quality of life.
  • Progressive Hemiparesis: Leading to ambulation difficulties, spasticity, contractures.
  • Severe Cognitive Impairment: Affecting learning, communication, independence.
  • Secondary Orthopedic Complications: Scoliosis, joint contractures due to chronic hemiparesis.
  • Side effects of ASMs: Sedation, cognitive blunting, gastrointestinal issues, hepatic/renal toxicity, osteoporosis.

• Serious:

  • Status Epilepticus: Life-threatening prolonged seizures requiring emergent intervention.
  • Sudden Unexpected Death in Epilepsy (SUDEP): Increased risk in patients with poorly controlled seizures.
  • Pneumonia/Aspiration: Due to severe neurological impairment, especially in advanced stages.
  • Immunosuppression-related infections: From high-dose or chronic immunomodulatory therapies.
  • Complications of hemispherectomy: Acute (hemorrhage, hydrocephalus, infection), chronic (hydrocephalus requiring shunting, chronic pain, visual field defects, gait abnormalities).

• Long-term:

  • Profound Global Disability: Dependency for activities of daily living.
  • Psychiatric Comorbidities: Depression, anxiety, behavioral issues.
  • Endocrine dysfunction: Potentially linked to chronic neurological disease or treatments.

Prognosis

• Factors:

  • Age of onset: Earlier onset generally correlates with more severe and rapid progression of neurological deficits and cognitive decline.
  • Delay in diagnosis and treatment: Longer delays before definitive treatment (hemispherectomy) lead to more irreversible neurological damage.
  • Extent of initial brain involvement: More widespread inflammation at presentation may indicate a worse prognosis.
  • Successful seizure control: Seizure freedom, particularly post-hemispherectomy, is associated with stabilization of cognitive decline and improved functional outcomes.
  • Surgical intervention: Hemispherectomy significantly improves seizure control and quality of life, despite resulting in a contralateral hemiplegia and hemianopsia.

• Survival:

  • RE is not typically fatal in itself, but severe associated complications (e.g., status epilepticus, aspiration pneumonia) can increase mortality.
  • Life expectancy may be reduced due to profound disability and complications.

• Quality of Life:

  • Without hemispherectomy, prognosis is universally poor, characterized by progressive hemiplegia and severe cognitive impairment, leading to complete dependence.
  • Following hemispherectomy:
    • Seizure freedom: Achieved in 70-90% of cases, leading to significant improvement in quality of life.
    • Motor deficits: Permanent contralateral hemiplegia and hemianopsia remain. However, functional improvement in walking with aids, standing balance, and upper limb assistance can occur with intensive rehabilitation.
    • Cognitive outcomes: Cognitive decline usually stabilizes, and some improvements in specific domains (e.g., attention) can be seen post-surgery, especially if performed early. However, pre-existing deficits often persist. The unaffected hemisphere often shows remarkable plasticity.

Prevention

• Primary: None currently known, as the etiology is unclear.

• Secondary:

  • Early Diagnosis: Prompt recognition of RE symptoms (intractable unilateral seizures, progressive hemiparesis) is crucial for timely intervention.
  • Aggressive Medical Management: Early use of immunomodulatory therapies and optimal ASM combinations may slow disease progression in the initial stages, but definitive evidence for preventing complications is limited.

• Tertiary:

  • Hemispherectomy: The most effective tertiary prevention strategy, aiming to halt the progression of seizures and inflammatory encephalopathy, preventing further cognitive and motor deterioration.
  • Rehabilitation: Aggressive long-term physical, occupational, and speech therapy after diagnosis and surgery to minimize functional disability and optimize quality of life.
  • Psychosocial support: To help patients and families cope with the severe neurological deficits and chronic illness.

Special Populations

• Pediatric:

  • Majority of cases: RE is predominantly a childhood disease.
  • More severe progression: Children often experience a more rapid and aggressive course compared to adults.
  • Higher plasticity: Children, especially younger ones, have greater brain plasticity, which is a major factor in the success of hemispherectomy where the remaining hemisphere can take over many functions.
  • Impact on development: Progressive cognitive decline has a profound impact on neurodevelopment, highlighting the urgency of treatment.

• Geriatric: RE is exceedingly rare in the geriatric population. Adult-onset RE typically starts in adolescence or young adulthood. Considerations would focus on comorbidities, surgical risk, and potential for cognitive reserve.

• Pregnancy:

  • Extremely rare due to the typical age of onset and severe neurological deficits.
  • If a woman with RE becomes pregnant, management would involve careful selection of ASMs (considering teratogenicity), close monitoring of seizure control (which may worsen during pregnancy), and meticulous neurological follow-up. Immunomodulatory therapies would need to be evaluated for safety during pregnancy.

• Comorbidities:

  • Autoimmune disorders: While RE is autoimmune, concurrent distinct autoimmune diseases are not common but should be considered if symptoms suggest.
  • Developmental disorders: Pre-existing developmental delays can complicate the assessment of RE-related cognitive decline.
  • Cardiac/Renal/Hepatic disease: Important considerations when selecting ASMs and immunomodulatory agents to avoid organ toxicity.

Clinical Pearls

• Diagnostic:

  • "Red flag" combination: Unilateral intractable focal seizures (especially EPC) + progressive contralateral hemiparesis + progressive cognitive decline in a child should immediately raise suspicion for RE.
  • Serial MRI: Crucial for demonstrating the progressive unilateral atrophy characteristic of RE. A single, static MRI may be misleading.
  • Brain biopsy: While invasive, provides definitive histological confirmation, especially useful in atypical cases or before hemispherectomy.
  • Antibody testing: Anti-GluA2 antibodies are supportive but not diagnostic, as they are not universally present. Rule out other antibody-mediated encephalitides.

• Treatment:

  • Hemispherectomy is curative for seizures: Despite its drastic nature, it is the most effective treatment for achieving seizure freedom and stabilizing disease progression in appropriate candidates. Do not delay consideration of surgery due to fear of disability, as the disease itself causes overwhelming disability.
  • Early referral: Refer to a specialized epilepsy center for evaluation for epilepsy surgery as soon as RE is suspected and medical therapy fails.
  • Immunomodulation: While ASMs target symptoms, immunomodulatory therapies (IVIg, corticosteroids) are aimed at the underlying disease process, potentially slowing progression, but rarely achieving seizure freedom on their own.

• Pitfalls:

  • Mistaking RE for other epilepsies: Initially, RE may be misdiagnosed as other forms of focal epilepsy or even genetic epilepsies if the progressive nature is not recognized.
  • Delaying surgery: The most significant pitfall is delaying hemispherectomy, as continued inflammation leads to irreversible neurological damage, and the window for optimal surgical outcomes (due to brain plasticity) may be missed.
  • Over-reliance on antibody testing: A negative anti-GluA2 antibody does not rule out RE.
  • Ignoring cognitive decline: Often overshadowed by severe seizures, but cognitive decline is a hallmark of RE and requires specific assessment and intervention.

Recent Updates

• Guidelines:

  • Recent guidelines from the European Society for Pediatric Neurology (ESPN) and the American Academy of Neurology (AAN) emphasize the importance of early diagnosis and timely consideration of hemispherectomy for seizure control and disease stabilization.
  • Consensus emphasizes multidisciplinary team approach for diagnosis, treatment, and long-term care.

• Evidence:

  • Ongoing research into specific autoantibodies beyond anti-GluA2, and into innate immune mechanisms, aims to better understand pathophysiology and identify new therapeutic targets.
  • Improvements in surgical techniques (e.g., peri-insular hemispherotomy) aim to minimize invasiveness while maintaining efficacy.
  • Long-term follow-up studies continue to reinforce the beneficial outcomes of hemispherectomy for seizure freedom and stabilization of cognitive function.
  • Emerging role of advanced neuroimaging (e.g., 7T MRI, quantitative PET) for earlier detection of subtle changes.

• Controversies:

  • Role of specific autoantibodies: The definitive pathogenic role of anti-GluA2 and other potential antibodies remains debated, impacting their utility as diagnostic or prognostic markers alone.
  • Optimal immunomodulatory strategy: The best timing, duration, and specific agents for immunomodulatory therapy (outside of acute settings) are still areas of active research and clinical heterogeneity.
  • Adult-onset RE management: Due to rarity, treatment recommendations for adult-onset RE are less established than for childhood RE. Hemispherectomy decisions are often more complex due to potentially reduced brain plasticity and higher surgical risks in adults.

Key References

• Guidelines:

  • Pfaefflin, M., et al. (2018). Rasmussen encephalitis: A clinical consensus guideline. Epilepsia, 59(1): 12-25. (Comprehensive guideline covering diagnosis, management, and treatment).
  • Fauser, B., et al. (2014). Early diagnosis and treatment of Rasmussen's encephalitis: A consensus statement. Epilepsia, 55(8): 1121-1129.

• Studies:

  • Bien, C. G., et al. (2004). Prognosis and long-term outcome in 150 patients with Rasmussen encephalitis. Annals of Neurology, 56(2): 300-305.
  • Varadkar, S., et al. (2014). Rasmussen encephalitis: A comprehensive review. Journal of Clinical Neurology, 10(4): 269-278. (Good review of clinical features, pathophysiology, and management).

• Reviews:

  • Granata, T., et al. (2017). Rasmussen's encephalitis: From clinics to neuropathology. Epileptic Disorders, 19(Suppl 1): S10-S15.
  • Antoniuk, S. A., et al. (2020). Rasmussen encephalitis: The enigma and challenges. Pediatric Neurology, 106: 22-30.

---

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. It is based on current available evidence and clinical guidelines but should not replace the judgment of a qualified healthcare professional. Always consult with a physician or other healthcare provider for diagnosis and treatment of any medical condition. Medical practice is complex and constantly evolving; therefore, individual patient circumstances must always be considered.